

Thailand Morning Cuppa

Top Story

Charoen Pokphand Foods (CPF TB, BUY, TP: THB35.00)

Needs More Time To Conclude; Stay BUY

Company Update

Keep BUY and THB35.00 TP, 27% upside plus 3.7% yield. While the Tesco stores acquisition here and Malaysia by the CP Group consortium will need more time to conclude – it still requires approvals from the regulators and other parties – we believe this could be earnings accretive to Charoen Pokphand Foods' bottomline. Other upsides include an increased hypermarket segment exposure and cost savings that could be leveraged from Tesco's logistics network.

Analyst: Pakorn Khaeian +66 2088 9627

Today's Report: [Charoen Pokphand Foods : Needs More Time To Conclude; Stay BUY \(10 Mar 2020\)](#)

Previous Report: [Charoen Pokphand Foods : Strong On All Fronts; Reiterate BUY \(24 Feb 2020\)](#)

Other Stories

PTT Exploration & Production (PTTEP TB, BUY, TP: THB120.00)

Earnings Slashed As The Bear Market Begins

Company Update

Maintain BUY with a new THB120.00 TP from THB147.00, 12% upside plus c.3.2% FY20F yield. As the OPEC+ meeting ended with no deal, we slash our crude oil price forecast for 2020 to USD47.00/bbl from USD62.30/bbl. Earnings and TP for PTT Exploration & Production are also revised down. While PTTEP's share price has already tumbled in correlation to crude oil prices, we believe its share price should recover over the course of this year.

Analyst: Kannika Siamwalla, CFA +66 2088 9744

Today's Report: [PTT Exploration & Production : Earnings Slashed As The Bear Market Begins \(9 Mar 2020\)](#)

Previous Report: [PTT Exploration & Production : An Eventful Year Ahead \(12 Feb 2020\)](#)

Bumrungrad Hospital (BH TB, NEUTRAL, TP: THB135.00) – DOWNGRADE

Outlook Dampened By COVID-19; D/G To NEUTRAL


Company Update

Downgrade to NEUTRAL from Trading Buy with a new THB135.00 TP from THB 157.00, 2% upside plus 2.4% yield. Despite the jump in share price due to speculation over the voluntary tender offer by Bangkok Dusit Medical Services (BDMS TB, BUY, TP: THB25.00), we are more cautious on Bumrungrad Hospital's operational outlook, given COVID-19 and pre-opening of projects that need more time to gear up.

Analyst: Pakorn Khaeian +66 2088 9627

Today's Report: [Bumrungrad Hospital : Outlook Dampened By COVID-19; D/G To NEUTRAL \(9 Mar 2020\)](#)

Previous Report: [Bumrungrad Hospital : 3Q19 And 9M19 Core Earnings Down 6% YoY \(8 Nov 2019\)](#)

Chart 1: SET intra-day graph


SET	2017	2018	2019	2020F
PE (x)	17.60	16.25	13.52	12.27
P/BV (x)	2.03	1.74	1.34	1.27
Yield (%)	2.80	3.35	3.79	4.00

SET Value by investor Type: Daily

	Buy (THBm)	Sell (THBm)	Net (THBm)
Institution	8,131.53	20,851.36	-12,719.83
Proprietary	9,511.80	8,554.23	957.57
Foreign	34,937.19	38,933.01	-3,995.82
Retail	51,043.23	35,285.15	15,758.08

SET Value by investor Type

	MTD (THBm)	YTD (THBm)
Institution	4,562.49	-11,699.61
Proprietary	-2,042.12	-2,824.45
Foreign	-20,138.52	-57,089.79
Retail	17,618.15	71,613.84

SET50 Index Future

	Long	Short	Net	MTD	YTD
Institution	73,600	101,704	-28,104	-23,124	-38,746
Foreign	144,538	136,464	8,074	46,186	78,129
Local	224,957	204,927	20,030	-23,062	-39,383

Foreign Fund Flows (USDm)

	Daily	WTD	MTD	YTD	YoY
Thailand	-126.8	-126.8	-639.7	-1828.5	4245.4

Note: *As at 9 Mar 2020 closing

Table 1: Key market indices (10 Mar 2020)

	Index	Chg	% Chg	% YTD
SET	1255.94	-108.63	-7.96%	-20.5%
SET50	827.85	-86.37	-9.45%	-22.5%
SET100	1822.83	-181.54	-9.06%	-22.2%
Dow Jones	23851.02	-2013.76	-7.79%	-16.4%
S&P500	2746.56	-225.81	-7.60%	-15.0%
Nasdaq	7950.68	-624.94	-7.29%	-11.4%
FTSE	5965.77	-496.78	-7.69%	-20.9%
FSSTI	2782.37	-178.61	-6.03%	-13.7%
Hang Seng	25040.46	-1106.21	-4.23%	-11.2%
Nikkei	19698.76	-1050.99	-5.07%	-16.7%
KLCI	1424.16	-58.94	-3.97%	-10.4%
SHANGHAI SE	2943.29	-91.22	-3.01%	-3.5%
JCI	5136.81	-361.73	-6.58%	-18.5%

Key Statistics
Foreign Exchange Rates / Oil Market

	Closed	Chg.	%Chg.
USD			
Baht (Onshore)	31.47	0.02	-0.08
Yen	112.00	-0.10	0.09
Euro	1.08	0.00	0.03
Oil Price (USD/barrel)			
Brent	58.50	-0.57	-0.96
Nymex-Crude Light	53.68	-0.20	-0.37

Note: *As at 9 Mar 2020 closing

Top BUYs

	TP (THB)	Upside (%)	Catalysts
Advance Info Service (ADVANC TB)	250.00	32.63	<ul style="list-style-type: none"> Better profitability due to the TOT litigation settlement (for towers and 2G equipment) that could decrease its network opex by THB3.2bn pa. Strong convergence services portfolio, with a low base of fixed broadband customers who should benefit from the shift in the industry's acquisition trends. Solid balance sheet and cash flow that could be a safeguard against uncertainties during the spectrum auction.
Bangkok Bank (BBL TB)	205.00	72.27	<ul style="list-style-type: none"> Improved sustainable earnings growth prospects, underpinned by continued loan growth, lower provisions, and efficient cost management. Sustainable earnings growth prospects, underpinned by continued loan growth, lower provisions, and efficient cost management. Moderate fee income growth is supported by the collaboration with AIA and less impact from the online fee waiver. ROE is trending up to 9-9.2% in 2019-2020 from the low level at 8.5% in 2017. As the top corporate lender, BBL is likely to gain the most benefits from the infrastructure investment cycle to shore up loans growth.
Bangkok Chain Hospital (BCH TB)	21.50	58.09	<ul style="list-style-type: none"> A leading private hospital and the Social Security Office (SSO) scheme's largest service provider. Enhanced its customer base to capture the upper-end and international patient segments. Key growth drivers are upcoming price adjustment and clearer payment policy from the SSO, higher revenue intensity from larger portion of cash patients who come for complicated cases, as well as better volume growth from upcoming new facilities and higher utilisation of World Medical Centre.
Central Pattana (CPN TB)	79.00	47.66	<ul style="list-style-type: none"> Following the online retail trend, the malls of Central Pattana – Thailand's No.1 shopping mall developer – are likely to become the centre of consumer lifestyle and activities. Expect better YoY earnings growth in 4Q19F compared to the previous quarter, to be driven by the major transfer of its three sold-out, high-rise residential projects. Loans refinancing may lower Grand Canal Land's cost of debts by c.0.5ppts by the final quarter this year, benefitting Central Pattana's interest expenses. Potentially, c. THB1.75bn net extra gains from the asset spin-offs to its REIT may be recorded in 1H20.
CP All (CPALL TB)	84.00	31.76	<ul style="list-style-type: none"> Its 7-Eleven convenience store outlook is likely on track – CP All continues to open new stores at the same 700 outlets pa rate it has undertaken so far, to enjoy sales from ongoing launches of new merchandise and the attractive stamp campaign, along with a recovery of service income thanks to rising transactions of its banking agent service. Siam Makro's product and customer developments play vital roles for the improvement of its operations, which have boosted sales and operating leverage. The factors help limit the impact of rising opex due to its overseas expansion. Expect stronger earnings growth of 13% in 2020F to be driven by both the 7-Eleven and Siam Makro segments.
CH Karnchang (CK TB)	26.00	44.44	<ul style="list-style-type: none"> With a small orderbook worth about THB37bn, the company has three construction projects. Remaining orders that can generate significant revenue in the near term include the mechanical & engineering system procurement contract for the Blue-Line Mass Rapid Transit (MRT) extension, Orange-Line MRT construction works under a JV with Sino-Thai Engineering & Construction, and the Xayaburi hydropower project in Laos. CK has signed new orderbooks worth about THB6bn from the Rama III-Dao Khanong Expressway. The company's opportunity to grow its orderbook will arise when high-speed railway network linking three international airports is scheduled for an upcoming contract signing.

Top BUYs

	TP (THB)	Upside (%)	Catalysts
Electricity Generating (EGCO TB)	371.00	53.31	<ul style="list-style-type: none"> We like this company for its relatively low gearing of 1x D/E and cash on hand of THB20.6bn, which we believe will support further growth in the overseas market. We expect 2020F earnings to be boosted by 10% to THB12.8bn, as two large scale projects have already commenced in 4Q19: The 500MW San Buenaventura Power in the Philippines and 1,285MW Xayaburi hydro-electric power plant in Laos.
Osotspa (OSP TB)	49.00	21.74	<ul style="list-style-type: none"> Osotspa's organisational streamlining by its new management team has effectively turned the company from a family business to a professionally run entity. Local and overseas activities to help driving topline sales, the launch of new products to capture consumer demands, expansion of production facilities, and distribution coverage abroad – mainly in Myanmar – to strengthen its leading position there. Its key business strategy – premiumisation of new products and corporate cost-savings programme – should be the key factors that help boost GPM and keep opex under control. Expect stronger earnings growth of 16% in 2020F vs 14% in 2019F.
PTT Exploration & Production (PTTEP TB)	120.00	60.54	<ul style="list-style-type: none"> The company's products are both directly and indirectly linked to crude oil prices, so it remains South-East Asia's best proxy to crude oil prices. We expect higher sales volume while costs remain stable. Its Leng Lebah (SK410B) field currently has estimated total resources at 2tcf. PTTEP expects to drill another nearby well in 2Q20. It is possible that another 2-3tcf can be found. This project could potentially be commercialised by 1Q25, as it could use shared existing facilities within the area. Assuming 30%-100% of 2tcf is proved reserves, this project could add c.TH3.50-11.50 per share to PTTEP's current valuation.
Siam Cement (SCC TB)	400.00	28.62	<ul style="list-style-type: none"> Among Siam Cement's major businesses, the cement & building materials division – along with the packaging wing – will somehow mitigate the heavy impact on the petrochemical business. This is based on management's guideline of proactive long-term measures to cope with macroeconomic uncertainties, eg the US-China trade war. While demand for cement has picked up since 3Q18, the company should leverage on this situation by introducing new high-value-added products in building materials and expanding its retail outlet network via partnerships made in major provincial cities.
Star Petroleum Refining (SPRC TB)	10.70	87.72	<ul style="list-style-type: none"> We like this company as share price has been depressed for most of 2019F due to its 45-day planned maintenance shutdown in 4Q19. After planned maintenance, we will see its refining capacity increase from 165kbpd to 175kbpd. We see earnings are set for a rebound, from net loss THB1.9bn for 2019F to net profit of THB5.0bn. The company has minimal debt, currently at USD51.8m temporary short-term debt. With its strong financial position, we believe the company is well placed for further expansion or diversification. We believe SPRC will make an announcement of its plans to expand into new business in 2Q20F. This new business, we believe, will be within its core competence and possibly downstream petrochemicals business.
WHA Corp (WHA TB)	4.85	80.97	<ul style="list-style-type: none"> WHA is the proxy in industrial estates to benefit from e-commerce in Thailand. After the company's successful deal with Alibaba, its key strength in premium warehouses should make it an attractive option for e-commerce players, especially from China. The stronger inflow of foreign direct investments (FDIs) into Thailand should bear fruit in 2019, when investors make decisions on the Eastern Economic Corridor's 10 target industries. Good signals from Chinese FDI investors, as they are requesting visits to WHA's project sites, especially for smart electronics, auto parts for electric vehicles, robotics, and food for the future.

Recent Stories

To access the following reports, please click on the link:

[RHB | Thailand Morning Cuppa : 9 March 2020](#)

[Regional Oil & Gas : No Deal For OPEC+, Price War Begins](#)

[Electricity Generating : Earnings Resilient Against COVID-19 Impact](#)

[PTT Exploration & Production : Earnings Slashed As The Bear Market Begins](#)

[Bumrungrad Hospital : Outlook Dampened By COVID-19; D/G To NEUTRAL](#)

[RHB | Thailand Morning Cuppa : 6 March 2020](#)

[Bangchak Corp : Challenging Year Ahead For Petroleum Business](#)

[RHB | Thailand Morning Cuppa : 5 March 2020](#)

[Land & Houses : Robust On All Fronts; Reiterate BUY](#)

[Inflation Slowed To 0.7% In Feb, Below BoT's Target Range](#)

[RHB | Thailand Morning Cuppa : 4 March 2020](#)

[Regional Oil & Gas : OPEC+ To Take Action As Demand Plummets](#)

[True Corp : Gloomy Outlook](#)

[RHB | Thailand Morning Cuppa : 3 March 2020](#)

[Amata Corp : Expecting Better Climate After The Blizzard; BUY](#)

[Bangkok Dusit Medical Services : Short-Term Impact From COVID-19; Keep BUY](#)

[Money Supply Growth Picks Up, But Remains Weak](#)

[RHB | Thailand Morning Cuppa : 2 March 2020](#)

[Regional Oil & Gas : The Price Of Uncertainty](#)

[Sino-Thai Engineering & Construction \(STEC TB\) : Flow Of New Jobs Ahead; Stay BUY](#)

[RHB | Thailand Morning Cuppa : 28 February 2020](#)

[Bangkok Expressway & Metro : Cash Cow Starts To Milk Again](#)

[Osotspa : Healthy Growth To Continue; Maintain BUY](#)

[RHB | Thailand Morning Cuppa : 27 February 2020](#)

[PTT Global Chemical: Waiting For a Rebound In 2H20](#)

[Supalai: Low-Risk Pick In The Basket; Maintain BUY](#)

[January MPI Down For Ninth Straight Month](#)

[RHB | Regional Morning Cuppa - 26 February 2020](#)

[Mega Lifesciences : Growth Remains Intact; Stay BUY](#)

[CP All : Best In Class In a Challenging Year; Maintain BUY](#)

[Thai Oil : A Rough Year Ahead](#)

[RHB | Thailand Morning Cuppa : 25 February 2020](#)

[PTT : Market Uncertainty Provides Little Upside](#)

[Pruksa Holding : Dim Outlook For a New Growth Cycle; Still SELL](#)

[January Trade Data Beats Estimates; Exports Up 3.4% YoY](#)

[RHB | Thailand Morning Cuppa : 24 February 2020](#)

[Charoen Pokphand Foods : Strong On All Fronts; Reiterate BUY](#)

[Central Pattana: Favourable 4Q19 Results; Keep BUY](#)

[Star Petroleum Refining : Looking At a Stronger 2H20F](#)

[RHB | Thailand Morning Cuppa : 21 February 2020](#)

[Total Access Communication : Keep TRADING BUY On Healthy Dividends](#)

[PTT : 2020F Set To Be a Challenging Year](#)

[RHB | Thailand Morning Cuppa : 20 February 2020](#)

[Global Power Synergy: Energy Transformation In The Works; U/G To BUY](#)

[Dynasty Ceramic: On a Gradual Uptrend; Keep BUY](#)

[Airports of Thailand : Mercy Measures For Partners; D/G To SELL](#)

[RHB | Thailand Morning Cuppa : 19 February 2020](#)

[IRPC: 1Q20 Earnings Could Be Weak](#)

RHB Guide to Investment Ratings

Buy: Share price may exceed 10% over the next 12 months

Trading Buy: Share price may exceed 15% over the next 3 months, however longer-term outlook remains uncertain

Neutral: Share price may fall within the range of +/- 10% over the next 12 months

Take Profit: Target price has been attained. Look to accumulate at lower levels

Sell: Share price may fall by more than 10% over the next 12 months

Not Rated: Stock is not within regular research coverage

Investment Research Disclaimers

RHB has issued this report for information purposes only. This report is intended for circulation amongst RHB and its affiliates' clients generally or such persons as may be deemed eligible by RHB to receive this report and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. This report is not intended, and should not under any circumstances be construed as, an offer or a solicitation of an offer to buy or sell the securities referred to herein or any related financial instruments.

This report may further consist of, whether in whole or in part, summaries, research, compilations, extracts or analysis that has been prepared by RHB's strategic, joint venture and/or business partners. No representation or warranty (express or implied) is given as to the accuracy or completeness of such information and accordingly investors should make their own informed decisions before relying on the same.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to the applicable laws or regulations. By accepting this report, the recipient hereof (i) represents and warrants that it is lawfully able to receive this document under the laws and regulations of the jurisdiction in which it is located or other applicable laws and (ii) acknowledges and agrees to be bound by the limitations contained herein. Any failure to comply with these limitations may constitute a violation of applicable laws.

All the information contained herein is based upon publicly available information and has been obtained from sources that RHB believes to be reliable and correct at the time of issue of this report. However, such sources have not been independently verified by RHB and/or its affiliates and this report does not purport to contain all information that a prospective investor may require. The opinions expressed herein are RHB's present opinions only and are subject to change without prior notice. RHB is not under any obligation to update or keep current the information and opinions expressed herein or to provide the recipient with access to any additional information. Consequently, RHB does not guarantee, represent or warrant, expressly or impliedly, as to the adequacy, accuracy, reliability, fairness or completeness of the information and opinion contained in this report. Neither RHB (including its officers, directors, associates, connected parties, and/or employees) nor does any of its agents accept any liability for any direct, indirect or consequential losses, loss of profits and/or damages that may arise from the use or reliance of this research report and/or further communications given in relation to this report. Any such responsibility or liability is hereby expressly disclaimed.

Whilst every effort is made to ensure that statement of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable and must not be construed as a representation that the matters referred to therein will occur. Different assumptions by RHB or any other source may yield substantially different results and recommendations contained on one type of research product may differ from recommendations contained in other types of research. The performance of currencies may affect the value of, or income from, the securities or any other financial instruments referenced in this report. Holders of depositary receipts backed by the securities discussed in this report assume currency risk. Past performance is not a guide to future performance. Income from investments may fluctuate. The price or value of the investments to which this report relates, either directly or indirectly, may fall or rise against the interest of investors.

This report does not purport to be comprehensive or to contain all the information that a prospective investor may need in order to make an investment decision. The recipient of this report is making its own independent assessment and decisions regarding any securities or financial instruments referenced herein. Any investment discussed or recommended in this report may be unsuitable for an investor depending on the investor's specific investment objectives and financial position. The material in this report is general information intended for recipients who understand the risks of investing in financial instruments. This report does not take into account whether an investment or course of action and any associated risks are suitable for the recipient. Any recommendations contained in this report must therefore not be relied upon as investment advice based on the recipient's personal circumstances. Investors should make their own independent evaluation of the information contained herein, consider their own investment objective, financial situation and particular needs and seek their own financial, business, legal, tax and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report.

This report may contain forward-looking statements which are often but not always identified by the use of words such as "believe", "estimate", "intend" and "expect" and statements that an event or result "may", "will" or "might" occur or be achieved and other similar expressions. Such forward-looking statements are based on assumptions made and information currently available to RHB and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement to be materially different from any future results, performance or achievement, expressed or implied by such forward-looking statements. Caution should be taken with respect to such statements and recipients of this report should not place undue reliance on any such forward-looking statements. RHB expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances after the date of this publication or to reflect the occurrence of unanticipated event. The use of any website to access this report electronically is done at the recipient's own risk, and it is the recipient's sole responsibility to take precautions to ensure that it is free from viruses or other items of a destructive nature. This report may also provide the addresses of, or contain hyperlinks to, websites.

RHB takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to RHB own website material) are provided solely for the recipient's convenience. The information and the content of the linked site do not in any way form part of this report. Accessing such website or following such link through the report or RHB website shall be at the recipient's own risk.

This report may contain information obtained from third parties. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content.

The research analysts responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously. The research analysts that authored this report are precluded by RHB in all circumstances from trading in the securities or other financial instruments referenced in the report, or from having an interest in the company(ies) that they cover.

The contents of this report is strictly confidential and may not be copied, reproduced, published, distributed, transmitted or passed, in whole or in part, to any other person without the prior express written consent of RHB and/or its affiliates. This report has been delivered to RHB and its affiliates' clients for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above. By electing to view or accepting a copy of this report, the recipients have agreed that they will not print, copy, videotape, record, hyperlink, download, or otherwise attempt to reproduce or re-transmit (in any form including hard copy or electronic distribution format) the contents of this report. RHB and/or its affiliates accepts no liability whatsoever for the actions of third parties in this respect.

The contents of this report are subject to copyright. Please refer to Restrictions on Distribution below for information regarding the distributors of this report. Recipients must not reproduce or disseminate any content or findings of this report without the express permission of RHB and the distributors.

The securities mentioned in this publication may not be eligible for sale in some states or countries or certain categories of investors. The recipient of this report should have regard to the laws of the recipient's place of domicile when contemplating transactions in the securities or other financial instruments referred to herein. The securities discussed in this report may not have been registered in such jurisdiction. Without prejudice to the foregoing, the recipient is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.

The term "RHB" shall denote, where appropriate, the relevant entity distributing or disseminating the report in the particular jurisdiction referenced below, or, in every other case, RHB Investment Bank Berhad and its affiliates, subsidiaries and related companies.

RESTRICTIONS ON DISTRIBUTION

Malaysia

This report is issued and distributed in Malaysia by RHB Investment Bank Bhd. The views and opinions in this report are our own as of the date hereof and is subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. RHB Investment Bank Bhd has no obligation to update its opinion or the information in this report.

Thailand

This report is issued and distributed in the Kingdom of Thailand by RHB Securities (Thailand) PCL, a licensed securities company that is authorised by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is a member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. RHB Securities (Thailand) PCL does not endorse, confirm nor certify the result of the Corporate Governance Report of Thai Listed Companies.

Indonesia

This report is issued and distributed in Indonesia by PT RHB Sekuritas Indonesia. This research does not constitute an offering document and it should not be construed as an offer of securities in Indonesia. Any securities offered or sold, directly or indirectly, in Indonesia or to any Indonesian citizen or corporation (wherever located) or to any Indonesian resident in a manner which constitutes a public offering under Indonesian laws and regulations must comply with the prevailing Indonesian laws and regulations.

Singapore

This report is issued and distributed in Singapore by RHB Securities Singapore Pte Ltd which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. RHB Securities Singapore Pte Ltd may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, RHB

Securities Singapore Pte Ltd accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact RHB Securities Singapore Pte Ltd in respect of any matter arising from or in connection with the report.

Hong Kong

This report is distributed in Hong Kong by RHB Securities Hong Kong Limited (興業僑豐證券有限公司) (CE No.: ADU220) (“RHBSHK”) which is licensed in Hong Kong by the Securities and Futures Commission for Type 1 (dealing in securities). Any investors wishing to purchase or otherwise deal in the securities covered in this report should contact RHBSHK. RHBSHK is a wholly owned subsidiary of RHB Hong Kong Limited; for the purposes of disclosure under the Hong Kong jurisdiction herein, please note that RHB Hong Kong Limited with its affiliates (including but not limited to RHBSHK) will collectively be referred to as “RHBHK.” RHBHK conducts a full-service, integrated investment banking, asset management, and brokerage business. RHBHK does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this research report. Investors should consider this report as only a single factor in making their investment decision. Importantly, please see the company-specific regulatory disclosures below for compliance with specific rules and regulations under the Hong Kong jurisdiction. Other than company-specific disclosures relating to RHBHK, this research report is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such.

United States

This report was prepared by RHB and is being distributed solely and directly to “major” U.S. institutional investors as defined under, and pursuant to, the requirements of Rule 15a-6 under the U.S. Securities and Exchange Act of 1934, as amended (the “Exchange Act”). Accordingly, access to this report via Bursa Marketplace or any other Electronic Services Provider is not intended for any party other than “major” US institutional investors, nor shall be deemed as solicitation by RHB in any manner. RHB is not registered as a broker-dealer in the United States and does not offer brokerage services to U.S. persons. Any order for the purchase or sale of the securities discussed herein that are listed on Bursa Malaysia Securities Berhad must be placed with and through Auerbach Grayson (“AG”). Any order for the purchase or sale of all other securities discussed herein must be placed with and through such other registered U.S. broker-dealer as appointed by RHB from time to time as required by the Exchange Act Rule 15a-6. This report is confidential and not intended for distribution to, or use by, persons other than the recipient and its employees, agents and advisors, as applicable. Additionally, where research is distributed via Electronic Service Provider, the analysts whose names appear in this report are not registered or qualified as research analysts in the United States and are not associated persons of Auerbach Grayson AG or such other registered U.S. broker-dealer as appointed by RHB from time to time and therefore may not be subject to any applicable restrictions under Financial Industry Regulatory Authority (“FINRA”) rules on communications with a subject company, public appearances and personal trading. Investing in any non-U.S. securities or related financial instruments discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in the United States. The financial instruments discussed in this report may not be suitable for all investors. Transactions in foreign markets may be subject to regulations that differ from or offer less protection than those in the United States.

Please refer to the following link ([RHB Research conflict disclosures – Mar 2020](#)) and the Disclosure of Conflict of Interest in each of the research reports provided in this email for more details.

Kuala Lumpur	Hong Kong	Singapore
RHB Investment Bank Bhd Level 3A, Tower One, RHB Centre Jalan Tun Razak Kuala Lumpur Malaysia Tel : +(60) 3 9280 8888 Fax : +(60) 3 9200 2216	RHB Securities Hong Kong Ltd. 12 th Floor World-Wide House 19 Des Voeux Road Central, Hong Kong Tel : +(852) 2525 1118 Fax : +(852) 2810 0908	RHB Securities Singapore Pte Ltd. 10 Collyer Quay #09-08 Ocean Financial Centre Singapore 049315 Tel : +(65) 6533 1818 Fax : +(65) 6532 6211
Jakarta		Bangkok
PT RHB Sekuritas Indonesia Revenue Tower 11th Floor, District 8 - SCBD Jl. Jendral Sudirman Kav 52-53 Jakarta 12190 Indonesia Tel : +6221 509 39 888 Fax : +6221 509 39 777		RHB Securities (Thailand) PCL 10th Floor, Sathorn Square Office Tower 98, North Sathorn Road, Silom Bangrak, Bangkok 10500 Thailand Tel: +(66) 2 088 9999 Fax : +(66) 2 088 9799